Navigation Links
Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
Date:2/16/2011

on and treatment of life-threatening or serious viral infections in immunocompromised patients," said Kenneth I. Moch, President and Chief Executive Officer of Chimerix. "We look forward to working with BARDA to harness the full potential of CMX001 to address the biodefense threat represented by smallpox."

"BARDA's support of the advanced development of CMX001 and their recognition of the role that Chimerix has in helping to assure the Nation's medical preparedness is an important step in addressing the threat of a smallpox attack," said George Painter, Ph.D., Chairman and Chief Scientific Officer of Chimerix. "Chimerix is fully committed to addressing unmet medical needs that have biodefense and global public health implications, especially for the most vulnerable groups in our population including children and the immunocompromised.  We look forward to working collaboratively with BARDA to progress CMX001."

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases.  Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes si
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
2. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
3. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
4. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
5. Chimerix to Present at Upcoming Investor Conferences
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
9. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
10. Chimerix Joins International Network of Organizations to Cure Malaria
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , Collaboration with Biomodels facilitates development ... Sept. 16 Avaxia Biologics, Inc., a biotechnology company developing oral ... that it has been awarded a Phase I SBIR grant from ... development of a novel antibody therapeutic for oral mucositis. , ...
... Sealers, cleaners, and ... , ... 16, 2009 - Tile Media Properties (TMP), best known for The Tile Doctor brand and ... The 10 year-old Atlanta-based company receives millions of unique visitors annually and is well-recognized as ...
... DIEGO, Sept. 16 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at the UBS Global Life Sciences Conference. The details ... September 22, 2009, Time: 2:30pm Eastern, ... Graham Cooper, Chief Financial Officer, , , ...
Cached Biology Technology:Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... common condition affecting 12-20 percent of Americans age 65 ... heart attack and strokeand many with the disease may ... Interventional Radiology. For more than a decade, the ... Life, has helped identify this very serious and potentially ...
... , This press release is available in German . ... as defined by the EU Water Framework Directive is unlikely to ... a study in which data from the four largest rivers in ... analysed over ten years. The study was carried out by the ...
... Agriculture (USDA) aerial photography survey of 38,000 wildfire-burned acres ... first evidence that the invasive leafy spurge weed is ... Booth, a rangeland specialist with the Agricultural Research Service ... the survey using a technique he developed called Very ...
Cached Biology News:Interventional radiologists: Learn about peripheral arterial disease and get moving 2Interventional radiologists: Learn about peripheral arterial disease and get moving 3Poor outlook for water quality in Germany 2Digital cameras open new view of America's West 2
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... EIA Principle: Glutathion-S-transferases (GST) ... are involved in the detoxification processes. ... subgroups: Alpha, Mu, Pi, Teta and ... physiochemical, immunological, enzymatic and s Sample ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
Biology Products: